Akari Therapeutics (NASDAQ:AKTX) Earns Sell Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a note issued to investors on Friday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Akari Therapeutics Stock Up 4.2 %

Shares of NASDAQ:AKTX opened at $1.00 on Friday. The business’s 50 day moving average is $1.82 and its 200 day moving average is $2.78. Akari Therapeutics has a 12-month low of $0.90 and a 12-month high of $4.40.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.